Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from $338.00 to $342.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would indicate a potential upside of 33.72% from the company’s previous […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from $338.00 to $342.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would indicate a potential upside of 33.72% from the company’s previous […]
